$JRSS
JRSIS HEALTH CARE Corp Stock $jrss

$jrss Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000114420417057924 Filed on November 13, 2017

Income Statement

Concept	2017 Q3	2016 Q4	2016 Q3
Revenue	$5.723M	$5.160M	$4.257M
YoY Change	34.43%	35.43%	45.4%
Cost Of Revenue	$1.573M	$1.510M	$1.162M
YoY Change	35.41%	49.5%	38.87%
Gross Profit	$4.150M	$3.650M	$3.095M
YoY Change	34.06%	30.36%	48.02%
Gross Profit Margin	72.51%	70.74%	72.71%
Selling, General & Admin	$980.0K	$800.0K	$760.0K
YoY Change	28.95%	26.98%	52.0%
% of Gross Profit	23.62%	21.92%	24.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$322.5K	$300.0K	$282.3K
YoY Change	14.23%	25.0%	22.42%
% of Gross Profit	7.77%	8.22%	9.12%
Operating Expenses	$2.300M	$1.960M	$1.590M
YoY Change	44.65%	38.03%	35.9%
Operating Profit	$1.502M	$1.690M	$1.171M
YoY Change	28.28%	22.46%	95.0%
Interest Expense	$351.1K	-$350.0K	$339.7K
YoY Change	3.36%	2.94%	7.46%
% of Operating Profit	23.38%	-20.71%	29.02%
Other Income/Expense, Net	$7.108K	$0.00	-$857.00
YoY Change	-929.4%		-74.73%
Pretax Income	$1.509M	$1.340M	$1.170M
YoY Change	28.98%	28.85%	95.96%
Income Tax	$437.00	$0.00	$866.00
% Of Pretax Income	0.03%	0.0%	0.07%
Net Earnings	$1.056M	$920.0K	$813.1K
YoY Change	29.87%	29.58%	104.92%
Net Earnings / Revenue	18.45%	17.83%	19.1%
Basic Earnings Per Share
Diluted Earnings Per Share	$63.47K	$55.09K	$48.50K
COMMON SHARES
Basic Shares Outstanding		13.92M shares	13.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.000M	$890.0K	$600.0K
YoY Change	66.67%	154.29%	27.66%
Cash & Equivalents	$999.6K	$890.7K	$597.0K
Short-Term Investments
Other Short-Term Assets	$880.0K	$580.0K	$540.0K
YoY Change	62.96%	123.08%	315.38%
Inventory	$1.080M	$801.2K	$810.0K
Prepaid Expenses		$518.7K
Receivables	$4.010M	$3.336M	$2.400M
Other Receivables	$3.650M	$1.555K	$1.580M
Total Short-Term Assets	$10.62M	$7.418M	$5.930M
YoY Change	79.09%	76.29%	117.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.26M	$23.27M	$24.38M
YoY Change	7.71%	3.68%	7.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$940.0K	$1.010M	$1.070M
YoY Change	-12.15%	-6.48%	5.94%
Total Long-Term Assets	$27.21M	$24.28M	$25.44M
YoY Change	6.96%	3.22%	7.03%
TOTAL ASSETS
Total Short-Term Assets	$10.62M	$7.418M	$5.930M
Total Long-Term Assets	$27.21M	$24.28M	$25.44M
Total Assets	$37.83M	$31.70M	$31.37M
YoY Change	20.59%	14.3%	18.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.510M	$743.7K	$910.0K
YoY Change	65.93%	110.79%	160.0%
Accrued Expenses	$60.00K	$50.00K	$50.00K
YoY Change	20.0%	25.0%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$590.0K	$0.00	$434.8K
YoY Change	35.7%		-14.75%
Long-Term Debt Due	$1.210M	$2.310M	$2.170M
YoY Change	-44.24%	22.87%	28.4%
Total Short-Term Liabilities	$4.120M	$3.218M	$3.639M
YoY Change	13.21%	30.77%	38.9%
LONG-TERM LIABILITIES
Long-Term Debt	$17.03M	$16.80M	$16.91M
YoY Change	0.71%	-5.94%	-2.48%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$17.03M	$16.80M	$16.91M
YoY Change	0.71%	-5.94%	-2.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.120M	$3.218M	$3.639M
Total Long-Term Liabilities	$17.03M	$16.80M	$16.91M
Total Liabilities	$27.72M	$20.02M	$20.55M
YoY Change	34.86%	-1.52%	-12.16%
SHAREHOLDERS EQUITY
Retained Earnings		$6.274M	$5.350M
YoY Change		123.9%
Common Stock		$1.146M	$1.146M
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.11M	$6.634M	$6.041M
YoY Change
Total Liabilities & Shareholders Equity	$37.83M	$31.70M	$31.37M
YoY Change	20.58%	14.3%	18.39%

Cashflow Statement

Concept	2017 Q3	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	$1.056M	$920.0K	$813.1K
YoY Change	29.87%	29.58%	104.92%
Depreciation, Depletion And Amortization	$322.5K	$300.0K	$282.3K
YoY Change	14.23%	25.0%	22.42%
Cash From Operating Activities	$2.280M	$1.080M	$490.0K
YoY Change	365.31%	-1.82%	-43.68%
INVESTING ACTIVITIES
Capital Expenditures	-$1.670M	-$130.0K	-$480.0K
YoY Change	247.92%	-90.71%	-64.18%
Acquisitions
YoY Change
Other Investing Activities		-$570.0K	$430.0K
YoY Change		-5800.0%	-23.21%
Cash From Investing Activities	-$540.0K	-$690.0K	-$50.00K
YoY Change	980.0%	-50.36%	-93.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.370M	-30.00K	-710.0K
YoY Change	92.96%	-108.57%	173.08%
NET CHANGE
Cash From Operating Activities	2.280M	1.080M	490.0K
Cash From Investing Activities	-540.0K	-690.0K	-50.00K
Cash From Financing Activities	-1.370M	-30.00K	-710.0K
Net Change In Cash	370.0K	360.0K	-270.0K
YoY Change	-237.04%	500.0%	58.82%
FREE CASH FLOW
Cash From Operating Activities	$2.280M	$1.080M	$490.0K
Capital Expenditures	-$1.670M	-$130.0K	-$480.0K
Free Cash Flow	$3.950M	$1.210M	$970.0K
YoY Change	307.22%	-51.6%	-56.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	64967	USD
CY2017Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	1754719	USD
CY2016Q4	us-gaap	Assets Assets	31702590	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	743660	USD
CY2016Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	5751	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	25329	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	77973	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	52072	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	2313038	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3217823	USD
CY2016Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16222992	USD
CY2016Q4	us-gaap	Liabilities Liabilities	20015736	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	13915	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1132423	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6274052	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-786055	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	6634335	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	5052519	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11686854	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31702590	USD
CY2017Q3	us-gaap	Deferred Costs DeferredCosts	121001	USD
CY2017Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	585898	USD
CY2016Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2017Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	819543	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	846101	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2407174	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1846898	USD
CY2017Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3315923	USD
CY2016Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	2410346	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	5723097	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	4257244	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1573420	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1161959	USD
CY2017Q3	jrss	Cost Of Medical Consumables CostOfMedicalConsumables	648258	USD
CY2016Q3	jrss	Cost Of Medical Consumables CostOfMedicalConsumables	382891	USD
CY2017Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	934950	USD
CY2016Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	720860	USD
CY2017Q3	us-gaap	Supplies Expense SuppliesExpense	249389	USD
CY2016Q3	us-gaap	Supplies Expense SuppliesExpense	70142	USD
CY2017Q3	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	22842	USD
CY2016Q3	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	17374	USD
CY2017Q3	us-gaap	Utilities Costs UtilitiesCosts	74222	USD
CY2016Q3	us-gaap	Utilities Costs UtilitiesCosts	76027	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7108	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1508896	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	437	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	1508459	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	452538	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	1055921	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	86880	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-203045	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1798384	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	539418	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1258966	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13915000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13915000	shares
	us-gaap	Professional Fees ProfessionalFees	126272	USD
	us-gaap	Depreciation Depreciation	936827	USD
	us-gaap	Depreciation Depreciation	779321	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	12176023	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9277435	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	3680677	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4403128	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3684577	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2072	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3172	USD
	us-gaap	Profit Loss ProfitLoss	4401056	USD
	us-gaap	Profit Loss ProfitLoss	3681405	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1320317	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.0759
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1501788	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	59064	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	92975	USD
	us-gaap	Interest Expense InterestExpense	980451	USD
	us-gaap	Interest Expense InterestExpense	1030949	USD
	us-gaap	Professional Fees ProfessionalFees	54182	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1133290	USD
	us-gaap	Net Income Loss NetIncomeLoss	3080739	USD
	us-gaap	Net Income Loss NetIncomeLoss	2548115	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	189867	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-77759	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-393121	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	195169	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	4984044	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	3408477	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1510184	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1055531	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3473860	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2352946	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.1831
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13915000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13915000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.2214
	us-gaap	Operating Income Loss OperatingIncomeLoss	4416283	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13155	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3900	USD
	us-gaap	Interest Expense Other InterestExpenseOther	980451	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	518881	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	445404	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	241598	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	333473	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	454662	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	446649	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	713214	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	303474	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	161232	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-191282	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-661	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-507	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	352153	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	597022	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2072	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-95108	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	68086	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4159891	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3914023	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	630043	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3346535	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2606774	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2918429	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2565420	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2149599	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1436584	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-747429	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-7547	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-3296	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	108986	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	244869	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3172	USD
	us-gaap	Interest Paid Net InterestPaidNet	980451	USD
	us-gaap	Interest Paid Net InterestPaidNet	1030949	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	1721979	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	531897	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	408836	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	421331	USD
	us-gaap	Interest Expense Other InterestExpenseOther	1030949	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	261101	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-428106	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	720000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	75985	USD
	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	0	USD
	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	904854	USD
	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	1715630	USD
	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	0	USD
CY2012Q4	jrss	Joint Venture Investment Obligation To Pay Capital JointVentureInvestmentObligationToPayCapital	5555556	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25	pure
CY2016Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3359619	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24119	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25521829	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2247649	USD
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13915000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13915000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13915000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13915000	shares
CY2016Q3	jrss	Capital Lease Financing Fees CapitalLeaseFinancingFees	349488	USD
CY2017Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.0609	pure
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	6775	USD
CY2016Q4	jrss	Prepaid Maintenance Cost PrepaidMaintenanceCost	1451136	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2548115	USD
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> C.</i></font></div> </td> <td> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i>Use of estimates</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> E.</i></font></div> </td> <td> <div><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><i> Concentration of Credit Risk</i></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the three months ended September 30, 2017 and 2016, no customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of net revenue. As of September 30, 2017 and December 31, 2016, 3 and 2 customers, respectively, accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	jrss	Consulting Fee ConsultingFee	16903	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5877	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	0	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5877	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	0	USD
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	171214	USD
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	774296	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	USD
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	0	USD
CY2016	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	0	USD

Files In Submission

Name	View Source	Status
0001144204-17-057924-index-headers.html	Edgar Link	pending
0001144204-17-057924-index.html	Edgar Link	pending
0001144204-17-057924.txt	Edgar Link	pending
0001144204-17-057924-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jrss-20170930.xml	Edgar Link	completed
jrss-20170930.xsd	Edgar Link	pending
jrss-20170930_cal.xml	Edgar Link	unprocessable
jrss-20170930_def.xml	Edgar Link	unprocessable
jrss-20170930_lab.xml	Edgar Link	unprocessable
jrss-20170930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv479164_10q.htm	Edgar Link	pending
tv479164_ex31-1.htm	Edgar Link	pending
tv479164_ex31-2.htm	Edgar Link	pending
tv479164_ex32-1.htm	Edgar Link	pending
tv479164_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JRSS
JRSIS HEALTH CARE Corp Stock $jrss

2017 Q3 Form 10-Q Financial Statement

#000114420417057924 Filed on November 13, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JRSS JRSIS HEALTH CARE Corp Stock $jrss

2017 Q3 Form 10-Q Financial Statement

#000114420417057924 Filed on November 13, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JRSS
JRSIS HEALTH CARE Corp Stock $jrss